HOUSTON, Aug. 17, 2017 /PRNewswire/ -- ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe viral infections, today announced notification of funding approval for a Product Development Research grant totaling $8.99 million by the Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee to support the clinical development of the Company's lead product, Viralym-M – a "ready to administer" multivirus-specific T cell immunotherapy.
Under the Product Development Research Program, CPRIT supports Texas-based companies and institutions by funding projects developing disruptive, commercially-oriented technologies with the overall goal of improving outcomes in patients with cancer. Pending successful negotiations and contract execution, the CPRIT award, entitled Improving Outcome of Stem Cell Transplants for Cancer Treatment Using Multi-Virus Specific T cells, will support an advanced clinical trial testing the safety and efficacy of Viralym-M in adult and pediatric cancer patients.
"ViraCyte is dedicated to improving the outcomes of stem cell transplant recipients and further developing T cell immunotherapy for viral complications for which there are no currently approved treatments available," stated Dr. Ann Leen, Chief Scientific Officer at ViraCyte. "We are extremely grateful to CPRIT and the Oversight Committee for their positive review and funding recommendation of this award."
About ViraCyte, LLC
ViraCyte's current products restore natural immunity against life threatening viruses in patients with severely weakened immune systems, such as adults and children who have recently undergone a hematopoietic stem cell transplant (HSCT). ViraCyte's lead T cell products are in Phase 2 and Phase 1 clinical trials, with effectiveness rates of greater than 94% in patients who have failed conventional therapy. More information can be found at www.viracyte.com
ViraCyte is a resident company at JLABS @ TMC, Houston, Texas.
SOURCE ViraCyte, LLC